Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Acquired by Northern Trust Corp

Northern Trust Corp lifted its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 8.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 628,580 shares of the company's stock after buying an additional 48,491 shares during the quarter. Northern Trust Corp owned about 1.05% of Protagonist Therapeutics worth $24,263,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of the stock. Bank of Montreal Can lifted its position in Protagonist Therapeutics by 4.5% during the 4th quarter. Bank of Montreal Can now owns 6,250 shares of the company's stock valued at $241,000 after acquiring an additional 270 shares during the period. Maryland State Retirement & Pension System lifted its holdings in shares of Protagonist Therapeutics by 1.4% during the fourth quarter. Maryland State Retirement & Pension System now owns 20,170 shares of the company's stock valued at $779,000 after purchasing an additional 278 shares during the last quarter. Nisa Investment Advisors LLC lifted its holdings in shares of Protagonist Therapeutics by 10.4% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,133 shares of the company's stock valued at $121,000 after purchasing an additional 295 shares during the last quarter. Louisiana State Employees Retirement System boosted its position in shares of Protagonist Therapeutics by 1.1% in the 4th quarter. Louisiana State Employees Retirement System now owns 28,800 shares of the company's stock worth $1,112,000 after purchasing an additional 300 shares in the last quarter. Finally, KBC Group NV grew its stake in shares of Protagonist Therapeutics by 54.4% in the 4th quarter. KBC Group NV now owns 2,093 shares of the company's stock worth $81,000 after buying an additional 737 shares during the last quarter. 98.63% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Protagonist Therapeutics news, CEO Dinesh V. Ph D. Patel sold 5,359 shares of the stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $38.18, for a total value of $204,606.62. Following the sale, the chief executive officer now owns 540,260 shares in the company, valued at $20,627,126.80. This trade represents a 0.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Asif Ali sold 1,756 shares of the business's stock in a transaction on Tuesday, April 22nd. The shares were sold at an average price of $46.00, for a total transaction of $80,776.00. Following the sale, the chief financial officer now directly owns 61,065 shares of the company's stock, valued at $2,808,990. This represents a 2.80% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 66,532 shares of company stock worth $3,665,786. Corporate insiders own 5.40% of the company's stock.

Wall Street Analysts Forecast Growth

PTGX has been the subject of a number of recent research reports. HC Wainwright reiterated a "buy" rating and set a $80.00 price objective on shares of Protagonist Therapeutics in a research note on Thursday, April 10th. JPMorgan Chase & Co. upped their price target on shares of Protagonist Therapeutics from $53.00 to $57.00 and gave the stock an "overweight" rating in a research note on Tuesday, March 4th. JMP Securities reissued a "market outperform" rating and set a $58.00 price objective on shares of Protagonist Therapeutics in a research report on Friday, February 7th. Truist Financial upped their target price on shares of Protagonist Therapeutics from $60.00 to $76.00 and gave the stock a "buy" rating in a research note on Tuesday, March 11th. Finally, BTIG Research set a $73.00 price target on shares of Protagonist Therapeutics in a report on Monday, March 3rd. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Protagonist Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $65.44.

Protagonist Therapeutics Price Performance

Shares of NASDAQ:PTGX traded up $0.08 during midday trading on Friday, hitting $44.49. The company had a trading volume of 647,034 shares, compared to its average volume of 873,969. Protagonist Therapeutics, Inc. has a 12-month low of $27.00 and a 12-month high of $60.60. The company has a market cap of $2.76 billion, a price-to-earnings ratio of 16.73 and a beta of 2.65. The company has a fifty day moving average of $47.07 and a two-hundred day moving average of $42.65.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.19) earnings per share for the quarter, beating analysts' consensus estimates of ($0.50) by $0.31. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%. The firm had revenue of $28.32 million during the quarter, compared to analyst estimates of $30.44 million. Research analysts expect that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current fiscal year.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.